1Department of Biology, Faculty of Natural Sciences & Health Care, Batumi Shota Rustaveli State University, Batumi, Georgia
2Research Unit on Applied Molecular Biosciences (UCIBIO), Rede de Química e Tecnologia (REQUIMTE), Faculty of Pharmacy, University of Porto, Porto, Portugal
3Department of Clinical Medicine, Faculty of Natural Sciences & Health Care, Batumi Shota Rustaveli State University, Batumi, Georgia
5Department of Internal Medicine, Faculty of Medicine, Tbilisi State Medical University, Tbilisi, Georgia
4Department of Public Health and Evidence-Based Medicine, Faculty of Natural Sciences & Health Care, Batumi Shota Rustaveli State University, Batumi, Georgia
6Dept. of Gynecologic Oncology, Advent Health Cancer Institute, Orlando, FL, 32804, USA
Cardiovascular disorders (CVD) broadly include coronary heart disease, stroke, congenital heart disease, peripheral artery disease, deep vein thrombosis, and other less common conditions. The risk factors for arterial thrombosis are usually divided into those that are modifiable and nonmodifiable. Herein, we aimed to characterize a cohort of arterial thrombosis patients from the Georgian Adjarian population.
In this study, 89 arterial thrombosis patients (male=71.3%, female=28.7%)were enrolled. Patients ’mean age was 66.3± 12.1 years. Troponin levels from the venous blood from patients and computed tomography (CT) assessments were used for myocardial infarction (MI) and ischemic stroke diagnosis. The venous blood from arterial thrombosis patients were used for polymerase chain reaction (PCR). PCR was performed to determine the presence of three genetic markers of thrombosis risk, viz., factor V Leiden (FVL) G1691A, prothrombin (PT) G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms.
In all, 83% of cases were diagnosed with MI and 13% with ischemic stroke. Also, 22.5% of the patients had diabetes, 73% hypertension, 49.3% had a family history of thrombosis, 34.8% consumed alcohol regularly (all males), and 63.4% of cases were smokers. The frequency of the FVL allele polymorphism in our cohort was 2.25%, which corresponded to a heterozygous frequency of 4.5%. The frequency of heterozygosity for the PT G20210A polymorphism was 2.25%; while the frequency of the MTHFR C677T allele polymorphism was 31.46%, which corresponded to heterozygous and homozygous stage frequencies of 51.7% and 5.6%, respectively.
In conclusion, we described the first cohort of arterial thrombosis patients in the Georgian Adjarian population, and the description of the clinical and molecular characteristics of patients with arterial thrombosis thus obtained may be useful to researchers, healthcare professionals, and policy makers while making decisions regarding the prevention, treatment, and follow-up of such patients.
Arterial thrombosis, Myocardial infarction, Ischemic stroke, FVL G1691A, PT G20210A, MTHFR (C677T), gene polymorphisms
